Updates are available Correction dated 2016-10-17

Click to view Correction: https://doi.org/10.1007/s10147-016-1052-3

Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer

Crossref DOI link: https://doi.org/10.1007/s10147-016-1039-0

Published Online: 2016-09-22

Published Print: 2017-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark